Literature DB >> 6259612

[Cefotaxime in bronchopulmonary infections (author's transl)].

J Kermarec, J Sauvaget.   

Abstract

Thirty-nine patients, 17 to 80 years old, were admitted to a pneumology department. The diagnosis was acute serious or severe respiratory tract infection in 25 patients, exacerbation of chronic bronchopulmonary infection in 6, purulent pneumonia in 4, purulent bronchitis in 4. 28 infecting organisms were identified: Gram-positive cocci (Pneumococcus: 6, Streptococcus: 8. Staphylococcus: 1) and 6 Haemophilus influenzae (3 of which were associated with 1 Pneumococcus) 7 Enterobacteria (isolated or associated). Local, biological and systemic tolerance was generally very good in the majority of patients. Cefotaxime at a daily dose of 2 g intramuscularly for 12 days, showed very good efficacy in the treatment of various bacterial infections of the lower respiratory tract. The activity was evident against a variety of organisms in respiratory infections. The in vitro results of the antibiogram which indicated a superiority of cefotaxime in some cases on other antibiotics currently used in these indications were confirmed by the clinical results.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259612

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  1 in total

Review 1.  Cefotaxime optimal dosage in adult patients. A reappraisal.

Authors:  A Simon; C A d'Aubrac; C Safran; C Carbon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.